Your browser doesn't support javascript.
loading
Targeted Degradation of PARP14 Using a Heterobifunctional Small Molecule.
Wigle, Tim J; Ren, Yue; Molina, Jennifer R; Blackwell, Danielle J; Schenkel, Laurie B; Swinger, Kerren K; Kuplast-Barr, Kristy; Majer, Christina R; Church, W David; Lu, Alvin Z; Mo, Jason; Abo, Ryan; Cheung, Anne; Dorsey, Bryan W; Niepel, Mario; Perl, Nicholas R; Vasbinder, Melissa M; Keilhack, Heike; Kuntz, Kevin W.
Affiliation
  • Wigle TJ; Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA.
  • Ren Y; Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA.
  • Molina JR; Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA.
  • Blackwell DJ; Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA.
  • Schenkel LB; Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA.
  • Swinger KK; Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA.
  • Kuplast-Barr K; Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA.
  • Majer CR; Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA.
  • Church WD; Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA.
  • Lu AZ; Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA.
  • Mo J; Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA.
  • Abo R; Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA.
  • Cheung A; Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA.
  • Dorsey BW; Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA.
  • Niepel M; Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA.
  • Perl NR; Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA.
  • Vasbinder MM; Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA.
  • Keilhack H; Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA.
  • Kuntz KW; Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA.
Chembiochem ; 22(12): 2107-2110, 2021 06 15.
Article in En | MEDLINE | ID: mdl-33838082
PARP14 is an interferon-stimulated gene that is overexpressed in multiple tumor types, influencing pro-tumor macrophage polarization as well as suppressing the antitumor inflammation response by modulating IFN-γ and IL-4 signaling. PARP14 is a 203 kDa protein that possesses a catalytic domain responsible for the transfer of mono-ADP-ribose to its substrates. PARP14 also contains three macrodomains and a WWE domain which are binding modules for mono-ADP-ribose and poly-ADP-ribose, respectively, in addition to two RNA recognition motifs. Catalytic inhibitors of PARP14 have been shown to reverse IL-4 driven pro-tumor gene expression in macrophages, however it is not clear what roles the non-enzymatic biomolecular recognition motifs play in PARP14-driven immunology and inflammation. To further understand this, we have discovered a heterobifunctional small molecule designed based on a catalytic inhibitor of PARP14 that binds in the enzyme's NAD+ -binding site and recruits cereblon to ubiquitinate it and selectively target it for degradation.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Poly(ADP-ribose) Polymerases / Small Molecule Libraries Limits: Humans Language: En Journal: Chembiochem Journal subject: BIOQUIMICA Year: 2021 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Poly(ADP-ribose) Polymerases / Small Molecule Libraries Limits: Humans Language: En Journal: Chembiochem Journal subject: BIOQUIMICA Year: 2021 Type: Article Affiliation country: United States